



User Evaluation

User evaluation of injection pen needles in Sweden, comparing Ypsomed's pen needle and a competitor twist-on pen needle

Objective

The primary objective of this evaluation was to assess the function and patient acceptance of Ypsomed's "click-on" pen needle versus a competitor twist-on pen needle with patients using a leading injection device. The needle sizes used were 31G × 5/16" (8 mm × 0.25 mm). The evaluation was performed by an independent Swedish institution (IBD – International Business Development, Sigtuna).

Methods

195 type I diabetics (78 female, 117 male) currently using a leading injection device with a competitor twist-on pen needle, were involved in the evaluation. The patients were recruited from 20 different medical centers in Sweden and they used "click-on" pen


needles over a period of 4 weeks for all their respective daily injections. Each patient performed an average of 4 injections per day, all of them by themselves.

Results

The average length of time the patients had been using an insulin pen was 7 years. Though the needles are single-use devices, only 48% (82 patients) were using it only once. All other patients were re-using their needles for convenience purposes and some of them even up to six times. The vast majority of patients (193 patients) considered the length of their current needle – with an 8 mm needle length – to be the preferred one for them.

Needle preferences

64% (125 patients) stated that they preferred the en needle.



Rating of individual needle characteristics

Comparing pen needle and a competitor twist-on pen needle

- 77% (150 patients) stated the attachment of the pen needle to be easier due to the "click-on" feature
- 28%/24% (50/43 patients) considered the injection comfort/ the sharpness of the pen needle superior to the competitor twist-on pen needle
- 13% (25 patients) considered the needle cap of the pen needle to be better

No significant distinction was made between both needles with regard to a lack of needle clogging, a lack of needle bending and the ease of dispensing dose.


Study results are based on Penfine[®] pen needles. The Clickfine[®] pen needles show the same design features regarding the needle hub. Therefore, in terms of the shown study results Penfine[®] and Clickfine[®] pen needles are comparable.



In an overall performance comparison of pen needle versus a competitor twist-on pen needle the following ratings were mentioned:


Likelihood of using pen needle

82% (160 patients) said they would be “likely” to use the pen needle with 92 patients considering themselves “very likely” to use it.



Likelihood of pen needle recommending

87% (170 patients) said they would recommend the new pen needle to a friend or colleague.




Conclusions

As a result of the performed acceptance evaluation, the majority of patients clearly demonstrated a preference in pen needle characteristics. Particularly, the perception of the simple attachment with the “click-on” feature, the recapping and the injection comfort showed that pen needle is a remarkably well accepted and a very competitive product if compared to a conventional twist-on pen needle.

Pen needle with click-on technology

Pen needles with click-on technology are manufactured in Switzerland by Ypsomed AG and sold internationally as Penfine[®] pen needles. They are also distributed in the U.S. by Perrigo where they are sold in pharmacies nationwide under the Clickfine[®] brand name and under retailers’ store brand names.

For electronic copies of this and other studies, visit myClickfine.com.



® Clickfine[®] is a registered trademark of Tecpharma Licensing AG, an affiliate of Ypsomed AG.